NCCN Task Force: Transfusion and Iron Overload in Patients With Myelodysplastic Syndromes

The National Comprehensive Cancer Network (NCCN) convened a multidisciplinary task force to critically review the evidence for iron chelation and the rationale for treatment of transfusional iron overload in patients with myelodysplastic syndromes (MDS). The task force was charged with addressing issues related to tissue iron toxicity; the role of MRI in assessing iron overload; the rationale and role of treating transfusional iron overload in patients with MDS; and the impact of iron overload on bone marrow transplantation. This report summarizes the background data and ensuing discussion from the NCCN Task Force meeting on transfusional iron overload in MDS.

If the inline PDF is not rendering correctly, you can download the PDF file here.

References

  • 1

    GreenbergP. The role of hemopoietic growth factors in the treatment of myelodysplastic syndromes. Int J Ped Hem-Onc1997;4:231238.

  • 2

    GreenbergPAttarEBattiwallaM. NCCN Clinical Practice Guidelines in Oncology: Myelodysplastic Syndromes version 2.2010. Available at: http://www.nccn.org. Accessed December 11 2009.

    • Search Google Scholar
    • Export Citation
  • 3

    ZurloMGDe StefanoPBorgna-PignattiC. Survival and causes of death in thalassaemia major. Lancet1989;2:2730.

  • 4

    HershkoCMLinkGMKonijnAMCabantchikZI. Iron chelation therapy. Curr Hematol Rep2005;4:110116.

  • 5

    OlivieriNFBrittenhamGM. Iron-chelating therapy and the treatment of thalassemia. Blood1997;89:739761.

  • 6

    MalcovatiL. Impact of transfusion dependency and secondary iron overload on the survival of patients with myelodysplastic syndromes. Leuk Res2007;31(Suppl 3):S26.

    • Search Google Scholar
    • Export Citation
  • 7

    AndrewsNC. Iron homeostasis: insights from genetics and animal models. Nat Rev Genet2000;1:208217.

  • 8

    HershkoCLinkGCabantchikI. Pathophysiology of iron overload. Ann N Y Acad Sci1998;850:191201.

  • 9

    CortelezziACattaneoCCristianiS. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis?Hematol J2000;1:153158.

    • Search Google Scholar
    • Export Citation
  • 10

    CabantchikZIBreuerWZanninelliGCianciulliP. LPI-labile plasma iron in iron overload. Best Pract Res Clin Haematol2005;18:277287.

  • 11

    EspositoBPBreuerWSirankaprachaP. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood2003;102:26702677.

    • Search Google Scholar
    • Export Citation
  • 12

    NemethETuttleMSPowelsonJ. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science2004;306:20902093.

    • Search Google Scholar
    • Export Citation
  • 13

    RiveraSLiuLNemethE. Hepcidin excess induces the sequestration of iron and exacerbates tumor-associated anemia. Blood2005;105:17971802.

    • Search Google Scholar
    • Export Citation
  • 14

    GattermannN. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk Res2007;31(Suppl 3):S1015.

    • Search Google Scholar
    • Export Citation
  • 15

    WinderALefkowitzRGhotiH. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br J Haematol2008;142:669671.

    • Search Google Scholar
    • Export Citation
  • 16

    OrigaRGalanelloRGanzT. Liver iron concentrations and urinary hepcidin in {beta}-thalassemia. Haematologica2007;92:583588.

  • 17

    PippardMJCallenderSTWarnerGTWeatherallDJ. Iron absorption and loading in beta-thalassaemia intermedia. Lancet1979;2:819821.

  • 18

    AndersonLJHoldenSDavisB. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J2001;22:21712179.

    • Search Google Scholar
    • Export Citation
  • 19

    WoodJCEnriquezCGhugreN. MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. Blood2005;106:14601465.

    • Search Google Scholar
    • Export Citation
  • 20

    WoodJCOtto-DuesselMAguilarM. Cardiac iron determines cardiac T2*, T2, and T1 in the gerbil model of iron cardiomyopathy. Circulation2005;112:535543.

    • Search Google Scholar
    • Export Citation
  • 21

    WoodJCEnriquezCGhugreN. Physiology and pathophysiology of iron cardiomyopathy in thalassemia. Ann N Y Acad Sci2005;1054:386395.

  • 22

    ChackoJPennellDJTannerMA. Myocardial iron loading by magnetic resonance imaging T2* in good prognostic myelodysplastic syndrome patients on long-term blood transfusions. Br J Haematol2007;138:587593.

    • Search Google Scholar
    • Export Citation
  • 23

    Di TucciAAMattaGDeplanoS. Myocardial iron overload assessment by T2* magnetic resonance imaging in adult transfusion dependent patients with acquired anemias. Haematologica2008;93:13851388.

    • Search Google Scholar
    • Export Citation
  • 24

    St PierreTGClarkPRChua-AnusornW. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood2005;105:855861.

    • Search Google Scholar
    • Export Citation
  • 25

    OlivieriNFNathanDGMacMillanJH. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med1994;331:574578.

    • Search Google Scholar
    • Export Citation
  • 26

    WoodJC. Cardiac iron across different transfusion-dependent diseases. Blood Rev2008;22(Suppl 2):1421.

  • 27

    ModellBKhanMDarlisonM. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson2008;10:42.

    • Search Google Scholar
    • Export Citation
  • 28

    WangRGrossCPHaleneSMaX. Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res2009;33:15941598.

    • Search Google Scholar
    • Export Citation
  • 29

    BujaLMRobertsWC. Iron in the heart. Etiology and clinical significance. Am J Med1971;51:209221.

  • 30

    DeleaTEHagiwaraMPhatakPD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr Med Res Opin2009;25:139147.

    • Search Google Scholar
    • Export Citation
  • 31

    TakatokuMUchiyamaTOkamotoS. Retrospective nationwide survey of Japanese patients with transfusion-dependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur J Haematol2007;78:487494.

    • Search Google Scholar
    • Export Citation
  • 32

    KaoJMMcMillanAGreenbergPL. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol2008;83:765770.

    • Search Google Scholar
    • Export Citation
  • 33

    KonenEGhotiHGoiteinO. No evidence for myocardial iron overload in multitransfused patients with myelodysplastic syndrome using cardiac magnetic resonance T2 technique. Am J Hematol2007;82:10131016.

    • Search Google Scholar
    • Export Citation
  • 34

    ParkJOhyashikiKAkataS. Evaluation of cardiac iron overload in transfusion-dependent adult marrow failure patients by magnetic resonance imaging. Leuk Res2009;33:756758.

    • Search Google Scholar
    • Export Citation
  • 35

    ArmandPKimHTCutlerCS. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood2007;109:45864588.

    • Search Google Scholar
    • Export Citation
  • 36

    PlatzbeckerUBornhauserMGermingU. Red blood cell transfusion dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndrome (MDS). Biol Blood Marrow Transplant2008;14:12171225.

    • Search Google Scholar
    • Export Citation
  • 37

    MalcovatiLPortaMGPascuttoC. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol2005;23:75947603.

    • Search Google Scholar
    • Export Citation
  • 38

    SchaferAICheronRGDluhyR. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med1981;304:319324.

  • 39

    JaegerMAulCSohngenD. Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes [in German]. Beitr Infusionsther1992;30:464468.

    • Search Google Scholar
    • Export Citation
  • 40

    GoldbergSLMody-PatelNChenER. Clinical and economic consequences of myelodysplastic myndromes in the United States: an analysis of the medicare database [abstract]. Blood2008;112:Abstract 636.

    • Search Google Scholar
    • Export Citation
  • 41

    CheeCESteensmaDPWuW. Neither serum ferritin nor the number of red blood cell transfusions affect overall survival in refractory anemia with ringed sideroblasts. Am J Hematol2008;83:611613.

    • Search Google Scholar
    • Export Citation
  • 42

    SanzGNomdedeuBSuchE. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome [abstract]. Blood2008;112:Abstract 640.

    • Search Google Scholar
    • Export Citation
  • 43

    LeitchHA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk Res2007;31(Suppl 3):S79.

    • Search Google Scholar
    • Export Citation
  • 44

    JensenPDHeickendorffLPedersenB. The effect of iron chelation on haemopoiesis in MDS patients with transfusional iron overload. Br J Haematol1996;94:288299.

    • Search Google Scholar
    • Export Citation
  • 45

    PorterJB. Practical management of iron overload. Br J Haematol2001;115:239252.

  • 46

    MaheshSGinzburgYVermaA. Iron overload in myelodysplastic syndromes. Leuk Lymphoma2008;49:427438.

  • 47

    ShashatyGFrankewichRChakrabortiT. Deferasirox for the treatment of chronic iron overload in transfusional hemosiderosis. Oncology (Williston Park)2006;20:179918061811.

    • Search Google Scholar
    • Export Citation
  • 48

    GoldbergSL. Novel treatment options for transfusional iron overload in patients with myelodysplastic syndromes. Leuk Res2007;31(Suppl 3):S1622.

    • Search Google Scholar
    • Export Citation
  • 49

    CappelliniMDBejaouiMAgaogluL. Prospective evaluation of patient-reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta-thalassemia. Clin Ther2007;29:909917.

    • Search Google Scholar
    • Export Citation
  • 50

    WimazalFNosslingerTBaumgartnerC. Deferasirox induces regression of iron overload in patients with myelodysplastic syndromes. Eur J Clin Invest2009;39:406411.

    • Search Google Scholar
    • Export Citation
  • 51

    CappelliniMDEl-BeshlawyAKattamisA. Efficacy and safety of deferasirox (Exjade(R)) in patients with transfusion-dependent anemias: 1-year results from the large, prospective, multicenter EPIC study [abstract]. Blood2008;112:Abstract 3875.

    • Search Google Scholar
    • Export Citation
  • 52

    PorterJBCappelliniMDEl-BeshlawyA. Effect of deferasirox (Exjade(R)) on labile plasma iron levels in heavily iron-overloaded patients with transfusion-dependent anemias enrolled in the large-scale, prospective 1-Year EPIC trial [abstract]. Blood2008;112:Abstract 3881.

    • Search Google Scholar
    • Export Citation
  • 53

    GattermannNSchmidMPortaMD. Efficacy and safety of deferasirox (Exjade(R)) during 1 year of treatment in transfusion-dependent patients with myelodysplastic syndromes: results from EPIC trial [abstract]. Blood2008;112:Abstract 633.

    • Search Google Scholar
    • Export Citation
  • 54

    ListAFBaerMRSteensmaD. Iron chelation with deferasirox (Exjade(R)) improves iron burden in patients with myelodysplastic syndromes (MDS) [abstract]. Blood2008;112:Abstract 634.

    • Search Google Scholar
    • Export Citation
  • 55

    RachmilewitzEMerkelDGhotiH. Improvement of oxidative stress parameters in MDS patients with iron overload treated with deferasirox [abstract]. Blood2008;112:Abstract 2675.

    • Search Google Scholar
    • Export Citation
  • 56

    De WitteTZwaanFHermansJ. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG). Br J Haematol1990;74:151155.

    • Search Google Scholar
    • Export Citation
  • 57

    DeegHJShulmanHMAndersonJE. Allogeneic and syngeneic marrow transplantation for myelodysplastic syndrome in patients 55 to 66 years of age. Blood2000;95:11881194.

    • Search Google Scholar
    • Export Citation
  • 58

    LucarelliGGalimbertiMPolchiP. Bone marrow transplantation in patients with thalassemia. N Engl J Med1990;322:417421.

  • 59

    KataokaKNannyaYHangaishiA. Influence of pretransplantation serum ferritin on nonrelapse mortality and nonmyeloablative allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant2009;15:195204.

    • Search Google Scholar
    • Export Citation
  • 60

    AlessandrinoEPDella PortaMGBacigalupoA. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica2009; in press.

    • Search Google Scholar
    • Export Citation
  • 61

    AltesARemachaAFSardaP. Frequent severe liver iron overload after stem cell transplantation and its possible association with invasive aspergillosis. Bone Marrow Transplant2004;34:505509.

    • Search Google Scholar
    • Export Citation
  • 62

    StrasserSIKowdleyKVSaleGEMcDonaldGB. Iron overload in bone marrow transplant recipients. Bone Marrow Transplant1998;22:167173.

  • 63

    KambleRTSelbyGBMimsM. Iron overload manifesting as apparent exacerbation of hepatic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant2006;12:506510.

    • Search Google Scholar
    • Export Citation
  • 64

    GreenbergPLCoslerLEFerroSALymanGH. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines. J Natl Compr Canc Netw2008;6:942953.

    • Search Google Scholar
    • Export Citation

Article Information

Cited By

PubMed

Google Scholar

Related Articles

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 92 92 30
PDF Downloads 41 41 6
EPUB Downloads 0 0 0